MEDICALGORITHMICS S.A.: Zamiana akcji imiennych serii J na akcje na okaziciela

Conversion
of Registered Series J Shares to Bearer Shares

Current
Report No.: 17/2024

Date:
August 19, 2024

Legal
Basis: Article 17(1) of the MAR Regulation – Confidential Information.

The
Management of Medicalgorithmics S.A., based in Warsaw (“Company”;
“Issuer”), informs that on August 19, 2024, a resolution was adopted
regarding the conversion of registered ordinary Series J shares into
bearer ordinary shares (“Resolution”). By virtue of the aforementioned
Resolution, the Company’s Management, acting on the basis of §5(4)
sentence 2 of the Company’s Articles of Association and Article 334 §2
of the Commercial Companies Code, at the request of the Company’s
shareholder – Biofund Capital Management LLC (“Shareholder”), converted
1,194,331 registered Series J shares with a nominal value of PLN 0.10
each from registered ordinary shares to bearer ordinary shares in the
same number: 1,194,331.

Before
the conversion, the Series J shares were registered ordinary shares, and
after the conversion, they became bearer ordinary shares belonging to
the Shareholder. The amount of the Company’s share capital after the
conversion remains unchanged at PLN 995,276.90. The total number of
votes at the Company’s general meeting after the conversion also remains
unchanged at 9,952,769.

The
Company reminds that in current report No. 55/2022 dated October 1,
2022, it informed that 4,976,384 shares, which were subscribed by
Biofund Capital Management LLC, based in Miami (USA), in accordance with
the investment agreement dated October 1, 2022, between the Company and
Biofund Capital Management LLC, are to be introduced to stock market
trading under the applicable exceptions from the obligation to prepare a
prospectus, with the planned date for introducing all these shares to
trading set for the end of 2026. Under this procedure, in June 2023,
995,276 bearer ordinary Series I shares of the Company were already
admitted to stock market trading, as indicated in current report No.
14/2023 dated June 14, 2023. This conversion of shares at the
Shareholder’s request was also carried out in execution of the
provisions of this investment agreement, i.e., for the purpose of
introducing Series J shares to stock market trading without the
obligation to prepare a prospectus, as indicated in current report No.
55/2022 dated October 1, 2022.

Zgłoś naruszenie/Błąd